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ABSTRACT 
Objective: Sentinel lymph node biopsy (SLNB) is a validated staging technique for breast carcinoma. Some women are 
exposed to have a second SLNB due to breast cancer recurrence or a second neoplasia (breast or other). Due to modi- 
fied anatomy, it has been claimed that previous axillary surgery represents a contra-indication to SLNB. Our objective 
was to analyse the literature to assess if a second SLNB is to be recommended or not. Methods: For the present study, 
we performed a review of all published data during the last 10 years on patients with previous axilla surgery and second 
SLNB. Results: Our analysis shows that second SLNB is feasible in 70%. Extra-axillary SNs rate (31%) was higher 
after radical lymph node dissection (ALND) (60% - 84%) than after SLNB alone (14% - 65%). Follow-up and com- 
plementary ALND following negative and positive second SLNB shows that it is a reliable procedure. Conclusion: The 
review of literature confirms that SLNB is feasible after previous axillary dissection. Triple technique for SN mapping 
is the best examination to highlight modified lymphatic anatomy and shows definitively where SLNB must be per- 
formed. Surgery may be more demanding as patients may have more frequently extra-axillary SN only, like internal 
mammary nodes. ALND can be avoided when second SLNB harvests negative SNs. These conclusions should however 
be taken with caution because of the heterogeneity of publications regarding SLNB and surgical technique. 
 
Keywords: Breast Neoplasms; Melanoma; Sentinel Lymph Node Biopsy Dissection; Lymphatic Vessels; Surgery; 
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1. Background 
Breast cancer has an incidence of 126/100,000 and is the 
commonest neoplasm in women [1]. Risk for ipsilateral 
breast cancer recurrence in women with early-stage 
breast cancer and breast-conserving therapy is about 5% 
- 20% [2]. On the other hand, melanoma has worldwide a 
growing incidence [3]. It is the fourth commonest neo- 
plasm in women with an incidence of about 15/100,000. 
Distribution of melanoma location shows a high density 
on the back, shoulders and upper arms in women [4]. It is 
not definitively established if breast cancer incidence 
after melanoma is increased or not compared to inci- 
dence in the general population [5,6]. In a large registry 
of 1926 men with breast cancer, Satram-Hoang showed 
that relative risk for melanoma was 2.98 (relative risk of 
52 for a second breast cancer) [7]. The study of Brower 
et al. showed that breast cancer was the commonest non 
skin second primary cancer in melanoma patients [8]. 
Due to these cancer incidences and some risks of re- 
currence, it is likely that women could be exposed to two 
sentinel lymph node biopsies (SLNB) or further surgery 
following radical axillary lymph node dissection (ALND). 
It has been initially claimed that previous axillary sur-  
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gery would represent a contra-indication to SLNB in 
breast cancer patients due to the modification of lym- 
phatic anatomy [9]. Subsequent observations and case 
studies have shown that 2 succeeding SLNB procedures 
for recurrent ipsilateral breast cancer were feasible [10].  
Our tertiary academic centre includes a melanoma 
clinic run by medical and surgical oncologists and an 
accredited breast cancer centre. After facing patients with 
melanoma and a past medical history of SLNB for breast 
cancer, we decided to investigate this rare condition (3 
out of 750 melanoma patients in our series). The purpose 
of our present study was to systematically review the 
literature in order to determine to what extent SLNB or 
ALND may alter lymphatic drainage and if a second 
SLNB could be considered reliable in this particular on- 
cological setting.  
2. Materials and Methods 
A web search (Ovid Medline®) was conducted over the 
last 10 years with following medical subject headings: 
sentinel lymph node biopsy, breast neoplasms, melanoma, 
second (title word), lymphatic anatomy and axilla. Fol- 
lowing identification of publications of interest, this 
search was completed by Medline tools using “similar 
references” or “citing references”. Case reports (1case) 
were discarded and some of these have been previously 
collected by Palit et al. [10]. Following data have been 
extracted: first axillary dissection (SLNB or ALND), 
success rate for second SLNB, number of patients and 
detailed sites for extra-axillary SLNB, rates of metastatic 
SN (sentinel node) and length of follow-up when avail- 
able. All these data are summarised in Table 1. Other 
data were reviewed such as: definition of SN and proto-
col for the SN anatomopathological examination.  
3. Results 
Our literature research totalizes 523 patients in 17 dif- 
ferent studies, which included between 2 and 117 pa- 
tients each (Table 1) [9,11-26]. Overall SN was succes- 
fully detected in 365/523 patients (70%). Extraaxillary 
SLNB was encountered in 114/365 patients (31%). This 
figure was quite variable throughout studies as all extra- 
axillary SN were not systematically searched for in all 
studies (especially internal mammary) despite the fact 
that there was a significant number of metastatic extra- 
axillary SNs. Extra-axillary locations included internal 
mammary, intramammary, interpectoral, parasternal, 
infraclavicular and cervical in. All these location have 
already been observed in primary SLNB for breast can- 
cer [27]. Keeping in mind that SNs were not all removed, 
we can acknowledge 46 and 13 patients with axillary and 
non-axillary metastatic SNs respectively. Clear definition 
for SN was scarce, triple technique for SLNB was not 
always the rule: blue dye was not systematically used in 
some series. Complete SNs analysis with H.-E. and im- 
munohistochemistry were performed in all but three 
studies [14,19,22]. A follow-up was available in half of 
the studies. No axillary recurrence was observed within a 
follow-up period ranging from 15 to 46 months. 
4. Discussion 
Our literature analysis shows data heterogeneity and lack 
of standardization of the various strategies. Despite this, 
our review suggests that SLNB after previous radical 
lymph node dissection in the same region is surgically 
feasible and seems oncologically to be reliable regarding 
the evaluation of potential lymphatic spreading of tumour 
cells. Lymphoscintigraphy should be regarded as the best 
examination tool for highlighting lymphatic anatomy and 
actual lymphatic drainage following a previous lympha- 
tic dissection in the same regional lymphatic network. 
Lymphoscintigraphy shows definitively basin(s) where a 
SLNB must be performed, especially for trunk melanoma, 
where drainage is frequently unpredictable [28]. 
The 17 reviewed publications (Table 1), have to be 
compared with caution because of several limitations: 1) 
heterogeneity of series due to different kind of initial 
breast surgery (benign and malignant disease with past 
SLNB, ALND or no axilla surgery), 2) blue dye injection 
was not systematically performed, and different injection 
technique (peritumoral, intratumoral, subcutaneously) 
were used, 3) no systematic ALND performed in case of 
SLNB failure, 4) variability of nodes detection rate dur- 
ing lymphoscintigraphy, 5) number of SNs retrieved and 
number of patients, 6) lack of follow-up in order to con- 
firm oncological value of second SLNB, among others. 
A negative SLNB in breast cancer exposes to 0.3% 
axillary recurrence only, within a median delay of 20 
months (range 4 - 63) [29]. So the follow-up reported in 
table 1 (range 15 - 46) could be an element for assessing 
that false negative results after second SLNB were con- 
trolled. 
ALND, which was a common procedure in patients 
with breast cancer in the past, is now replaced by sentinel 
lymph node dissection as a validated staging procedure. 
It is generally accepted that a micrometastatic disease in 
sentinel nodes does not oblige to perform ALND in pa- 
tients with breast cancer, while it is still a debated matter 
in melanoma patients. SLNB following previous breast 
and axillary surgery is another matter of debate. The 
number of metastatic lymph nodes is in parallel with the 
mean number of lymph nodes retrieved during a radical 
lymph node dissection. This mean number can be con-  
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2004, Sood [11] 4 (4/0) 4 100 4 2 0i/1c - 2b 1 + 0 NA 
2005, Dinan [12] 16 (2/14) 11 69 7 1 4i/3c 2i/1c 1
b 
1c 0 NA 
2005, Agarwal [13] 2 (0/2) 2 100 2 - 1i/2c   0 + 1 25 and 14/0
2006, Newman [14] 10 (1/7) 9 90 7 3 2i/7c - - 0 NA 
2006, Roumen [15] 12 (2/10) 10 83 7 3 6i/4c - 2i 3 + 2 24/0  (negative SN)
2006, Taback [16] 15 (11/9) 11 73 5 2 5i/3c 1i 2f 2 + 1 41/0 
2007, Port [9] 117 (54/63) d 64 55 19 11 52i/5c 1i 1
e 
3b 8 + 2 26.4/0 
2007, Intra [17] 65 (65/0) 63 97 5 4 63i/0c 1i - 6 + 1 45.9/0 
2007, Barone [18] 19 (7/12) 16 84 NA 16i   2 + 0 15/0 
2008, Koizumi [19] 31 (3/16) h 29 94 12 5 17i /7c - - 1 + 3 NA 
2008, Schrenk [20] 30 (13/13) g 19 63 5 4 15i /1c - 1f 4 + 0 NA 
2008, Cox [21] 56 (56/0) 45 80 1 1 45i/0c - - 9 + 0 NA 
2008, Axelsson [22] 47 (1/43) l 20/44 45 7 3l 24i/1c 2i 2i 7 NA 
2008, Karam [23] 20 (4/11) j 13 65 2 1 15i/0c 1i - 2 + 0 NA 
2009, Tasevski [24] 18 (3/15) 12 67 9 5 5i/5c - - 0 + 3 NA 
2010, Van  




















2010, Derkx [26] 13 (13/0) 5 38 NA - 5i - - 1 + 0 13/0 
Overall 523 365 70 114/365    46 + 13  
SLNB: previous sentinel lymph node biopsy. ALND: previous axillary radical lymph node dissection. IM: internal mammary. Other extra-axillary SNs: bin- 
tramammary, ccervical, einfraclavicular, finterpectoral, iclose to side of recurrence. NA: not assessed. ameans any SN outside ipsilateral axilla, patients had 
drainage to more than one basin (sometimes difficult to distinct number of nodes and number of patients). d115 patients: 2 had bilateral breast carcinoma. g 1 
patient had a previous axillary benign tissue resection and three melanoma surgery. h10 patients received radiotherapy to breast and axilla and 12 patients had 
breast surgery only. j1 patient had bilateral breast cancer, 5 patients had breast surgery only. kout of a series of 115 patients including previous breast surgery for 
benign pathology, overall 12 patients out of 115 had positive SN. l3 patients had a lumpectomy only and 3 were excluded because no blue dye was used. Inter- 
nal mammary SN were not. 
 
sidered as quality control surrogate marker in ALND. 
The median number of analysed lymph nodes was 13 
(range 1 - 51) in a large retrospective study on 31,679 
breast cancer patients [30]. There are important differ- 
ences in ALND in breast cancer or in melanoma. So a 
complete lymph node dissection has the not the same 
magnitude in breast cancer (usually limited to level I and 
II) when compared to melanoma (usually including level 
I to III). This may partly explain the possibility to per- 
form SLNB after previous “radical axillary dissection” in 
breast cancer patients. In melanoma patients ALND is 
regarded as a therapeutic procedure and as such it results 
in harvesting more lymph nodes than in breast cancer 
patients [31,32]. Redo ALND following previous ALND 
for breast cancer should be performed if necessary, be- 
cause it may yield a similar or even a higher number of 
nodes compared with previous initial ALND [18]. 
5. Comprehensive Anatomy of Lymphatics 
of the Upper Limb Trunk and Axilla 
Comprehensive reviews of upper limb and upper torso 
and breast lymphatic anatomies showed that lymphatics 
converge to a dominant axillary lymph node with nu-
merous connexions to defined territories along the limb 
[33-35]. Some studies have observed that in SLNB for 
breast cancer, dermal and parenchymal lymphatics drain 
to the very same axillary node(s) [36], but lymphatic 
watershed in the breast does exist, thus explaining physi-
ologic extra-axillary drainage. Based on Suami’s study, 
peritumoral dye/radiocolloid injection should be pre-
ferred [37]. There is often more than one first-tier node 
[37]. Lymphatic drainage of the upper limb may rarely 
Axillary Sentinel Lymph Node Biopsy for Breast Cancer and Melanoma Patients after Previous Axillary Surgery:  
A Systematic Review 
1398 
bypass level I and II of the axilla by using the way 
through lymphatics along cephalic vein and may drain 
directly in level III (infraclavicular fossa) [38]. This was 
already described in Sappey’s drawings [33]. There are 
some connexions between superficial and deep lymphatic 
network [33], these may also account for interval sentinel 
nodes [38]. Of note, opening of lymphatic connections 
between deep and superficial network may prevent lym- 
phedema after complete axillary dissection [39]. Varia- 
tion in lymphatic vessels anatomy was illustrated by 
Wall et al. in patients with SLNB for trunk and extremi- 
ties melanoma: this group showed that 30.5% of patients 
had multiple lymphatic channels draining to a single ba- 
sin, while 58.8% had one single lymph channel only 
identified from the primary tumour site [40].  
6. To What Extent Previous Surgery and  
Lymphatic Dissection (SLNB or ALND) in 
the Axilla Would Change the Lymphatic 
Network and the Success for Second 
SLNB? 
Luini et al. showed that a previous breast biopsy would 
not modify SLNB accuracy in a study with 543 breast 
cancer patients and a 99% SN identification rate [41]. In 
70 breast cancer patients with previous breast augmenta- 
tion or reduction surgery, SNs were identified in all and 
were positive in 32%. Only one patient had bilateral 
axillary drainage and ipsilateral internal mammary drain- 
age [42]. In another study, axillary SNs were seen in the 
axilla in 100% of patients following plastic surgery and 
in 91% after excisional biopsy only [25]. 
Table 1 shows that mean success rate for second 
SLNB was 70% (45% - 100%) and was clearly related to 
previous axilla surgery in the larger series where sub- 
groups were analysed: 38% after ALND and 74% after 
SLNB in Port’s study [9], 50% and 72% respectively in 
van der Ploeg’s study [25]. Schrenk et al. observed a 
63% successful SN detection rate, which correlated with 
a positive lymphoscintigraphy and less than 10 nodes 
removed during the first axillary surgery [20]. Axelsson 
et al. observed however that success for second SLNB 
was not related to the number of lymph nodes at first 
surgery [22]. 
Compared to radical lymph node dissection, SLNB 
shows significantly a lower risk for lymphedema: in 
4.6% - 16% for ALND patients and 0.3% - 5% for SLNB 
patients [43-45]. Lymphedema definition and measure- 
ment may vary, but there is a significantly increased risk 
with higher body weight, infection and injury after sur- 
gery [45]. Despite removal of a central key node or 
nearly all nodes, existing complex lymphatic network, 
accessory lymph channels or regenerated lymphatics may 
explain the fact that many patients did not experience 
lymphedema following a first axillary dissection [39]. 
Lymphedema risk following second axillary dissection is 
unfortunately not reported in the reviewed papers in Ta- 
ble 1.  
Fibrosis has been proven in an animal model as a key 
inhibitor in lymphatic regeneration. Extent of surgery or 
regional morbidity (lymphocele infection or lymphangitis) 
may explain why lymphatic anatomy is altered to various 
degrees [46]. Moreover, radiation and chemotherapy may 
also play a negative role in SN detection. Axillary dis- 
section followed or not by radiotherapy may alter lym- 
phatic drainage so that anterior chest may drain directly 
to internal mammary nodes [47,48]. Xing’s meta-analy- 
sis showed that SLNB was still reliable following induc- 
tion chemotherapy alone in breast cancer patients [49]. 
Some authors have observed that neither adjuvant radio- 
therapy [9,17,21] nor chemotherapy [9] affect SN identi- 
fication rate. Failures may also be explained by alteration 
of radiotracer detection by a change in lymphatic net- 
work (diffuse small lymphatics) due to fibrosis or be- 
cause of an enlarged metastatic lymph node. One study 
observed blue dye failure in 9/11 patients [12] and an- 
other observed that only 50% SNs were blue while 89% 
were hot [9], thus justifying the use of both tracer meth- 
ods.  
One interesting fact in table 1 is the proportion of 31% 
of extra-axillary SNs (15% - 100%) observed during sec- 
ond SLNB. This figure is in accordance with 6% - 33% 
reported in the literature for first SLNB [9,25,27]. Extra- 
axillary SNs were more frequently observed after ALND 
(60% - 84%) than after SLNB (14% - 65%) at first sur- 
gery [9,20,25]. These were mainly IM and contralateral 
axilla, many times following ALND at first surgery. 
Surgery for extra-axillary SN is more demanding due to 
the need for internal mammary nodes and scary tissues 
dissection for example [9,20,50]. 
In case of successful second SLNB, reliability of sec- 
ond SLNB was demonstrated either by 1) follow-up with 
negative axillary/extra-axillary recurrence, 2) by axillary 
dissection in patients with non-metastatic SN at second 
SLNB or 3) in patients where second SLNB failed. With 
a median follow-up of 45.9 months, Intra et al. did not 
observe any axilla recurrence in the 57 patients who had 
no further ALND after negative SLND [17]. Dinan et al. 
[12] had one single patient with SLNB at first surgery 
and negative SLNB at second surgery: a further ALND 
showed 14 negative nodes. In Schrenk’s study, 13 pa- 
tients out of 15 who had negative SN had a further 
ALND, which showed no other metastasis in a mean of 
14.3 nodes (5 - 24), with a false negative rate of 0% [20]. 
Karam et al. chose to perform complementary ALND in 
11 patients with successful second SLNB only in 4 pa- 
tients who had SLNB at first surgery: none had positive 
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nodes [23]. Port et al. removed additional non-SN in 23 
out of 54 patients with successful reoperation with nega- 
tive SN: one patient had positive internal mammary SN 
and the other a palpable positive non-SN [9]. Overall 
sensitivity and false negative rates were difficult to as- 
sess based because of incomplete data from table 1. 
Concomitant/sequential melanoma and breast cancer is 
indeed a rare event but was already described by Sood in 
2004 (1 patient out of 4) [11] and by Schrenk in 2008 (3 
out of 30) [20]. Collision tumours (SN with two his- 
tologically different metastatic deposits) with breast 
cancer and melanoma had a 0.5% incidence (52 cases in 
20 years) at The Moffitt Cancer Centre [51]. Simultane- 
ous neoplasms with only one of them detected can ex- 
pose either to collision tumour or destruction of lympha- 
tic pathways leading to a second metastatic undetected 
SN. In case of breast cancer a median delay of 20 months 
[29] would be necessary and only weeks for melanoma in 
order to observe a clinically or radiologically enlarged 
lymph node.  
7. What Should Be the Next Step for Patients 
Who Failed Second SLNB Detection?  
According to previous detection (SLNB or ALND) some 
authors propose surveillance [23]. Intra et al. detected 
positive nodes in one single such patient with a PET-CT 
[17], majority of authors propose in selected patients an 
ALND, who revealed positive nodes in 1/11 patients [19], 
1/2 patients (out of 11 failures) [21], 2/3 patients (out of 
7 failures) [23]. In the study of Port et al., 53 patients 
with failed second SLNB 29 had no further additional 
nodes and one patient out of 24 ALND (1-26 further 
nodes) had a metastatic lymph node [9]. Secondary ALND 
after a previous ALND is able to remove 0 - 16 further 
lymph nodes [12,16,18,20]. 
8. Conclusions 
Based on this comprehensive literature review, definitive 
conclusions are difficult to draw because of the rare con- 
dition, and because of the retrospective nature of the 
studies, the lack of complete survival data and data het- 
erogeneity. Patients with a second malignancy are also 
usually excluded from randomized trials. However, fol- 
lowing conclusions can be proposed: 
1) Previous axillary dissection (SLNB or level I-II 
lymph node dissection for breast cancer) does not pre- 
clude a new SLNB (feasible in 70%) and completion of 
ALND when positive SNs are detected. Even in more 
radical surgery for melanoma patients, SLNB would be 
able to detect where the actual lymphatic flow has been 
moved.  
2) Due to multiplicity of unusual drainage way, clas- 
sical triple technique of lymphatic mapping should be 
recommended, associating lymphoscintigraphy (dyna- 
mic/static), blue dye injection and intraoperative use of 
hand held gamma probe. Of note, SLNB rules must be 
respected: remove all enlarged suspicious non SN. 
3) In this setting when detected, extra-axillary SNs 
should be dissected as they may be the only SN and the 
only metastatic SN. Internal mammary SLNB is a stan- 
dardized procedure [27,31,47,50]. It is however impossi- 
ble to say if ALND can be avoided when only an extra- 
axillary SN is positive, in the same way as in a first 
SLNB [50]. 
4) In case of successful second axillary SLNB with 
negative SN and in case of extra-axillary SLNB with 
negative SN, the absence of recurrence in the present re- 
view indicates that avoidance of complementary ALND 
is a safe option.  
5) Complementary ALND should be discussed in case 
of failed second SLND. At least a strict follow-up com- 
bined with echography, CT-scan or PET-CT should be 
recommended.  
6) Complementary ALND should be discussed when 
SLNB is positive (regardless of previous ALND or 
SLNB) and in contralateral axilla in case of positive con- 
tralateral positive SN. 
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SN: sentinel lymph node; 
SLNB: sentinel lymph node biopsy; 
ALND: axillary radical lymph node dissection. 
 
